Scientists at the University of Virginia School of Medicine are chasing a new way to slow glioblastoma, the deadliest brain ...

Researchers at Texas A&M are pairing a widely used ingredient with advanced medical technology to develop new treatments for ...

A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...

Monash University researchers, in collaboration with Harvard University, have discovered how to permanently "switch off" ...

As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage ...

UVA scientists discovered a molecule that blocks a key gene that drives glioblastoma, offering hope for a new treatment ...

By targeting a cancer-driving pathway at multiple steps, a triple therapy stopped pancreatic tumors from developing ...

Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.

Zenocutuzumab--zbco, marketed as BIZENGRI (R), received Breakthrough Therapy Designation from the FDA in October 2025 and was granted accelerated approval in December 2024 for adults with advanced ...

AUSTIN, Texas, Oct. 14, 2025 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...

An experimental drug combination was able to effectively treat pancreatic cancer in mouse models without tumor resistance.

Gene therapy represents an innovative approach to treating cancer by directly modifying the genetic material within tumour cells, thereby utilising molecular mechanisms to inhibit tumour growth or ...